Pathophysiology of Na and water retention in liver cirrhosis and its correction with vasoconstrictors and aquaretics

Bibliography

• LEVY M: Renal function in dogs with acute selective hepatic venous outflow block. Am. J. Physiol. (1974) 227:1074-1083.
   PubMed Web of Science ®Google Scholar
• WITTE CL, WITTE MH, DUMONT AE: Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology (1980) 78:1059-1068.
   PubMed Web of Science ®Google Scholar
• WITTE CL, WITTE MH: Splanchnic circulatory and tissue fluid dynamics in portal hypertension. Fed. Proc. (1983) 42:1685-1689.
   PubMedGoogle Scholar
• HENRIKSEN JH, BENDTSEN TI, STADEAGER C, RING-LARSEN H: Reduced central blood volume in cirrhosis. Gastroenterology (1989) 97:1506-1513.
   PubMed Web of Science ®Google Scholar
• SATTA A, CONTU B, BRANCA GF, MENGHI R, BRESADOLA F, BARTOLI E: Importance of liver interstitial pressure on sodium retention. Nephron (1988) 49:190-196.
   PubMed Web of Science ®Google Scholar
• SATTA A, MENGHI R, FAEDDA R et al.: Changes in renal function following temporary occlusion of the thoracic duct. Front. Gastroint. Res. (1983) 8:1-9.
   Google Scholar
• SOGGIA G, OMEO NA, SATTA A et al.: The role of prostaglandins in Na retention of porta-cava shunted rats. Pharmacol. Res. Commun. (1984) 16:1065-1079.
   PubMedGoogle Scholar
• BARTOLI E, ROMANO G, FAVRET G: Micropuncture and clearance measurements of segmental reabsorption by the rat nephron. Nephrol. Dial. Transpl. (1996) 11:275-281.
   PubMed Web of Science ®Google Scholar
• BARTOLI E, ROMANO G, FAVRET G: Segmental reabsorption measured by micropuncture and clearance methods during hypertonic sodium infusion in the rat. Nephrol. Dial. Transpl. (1996) 11:1996-2003.
   PubMed Web of Science ®Google Scholar
• BARTOLI E, SATTA A, FAEDDA R, OLMEO NA, SOGGIA G, BRANCA G: A furosemide test in the functional evaluation of the human nephron in vivo. J. Clin. Pharm. (1983) 23:56-64.
   PubMed Web of Science ®Google Scholar
• BARTOLI E, ROMANO G: Measurements of reabsorption by single segments of the human nephron. J. Nephrol. (1999) 12:275-287.
   PubMed Web of Science ®Google Scholar
• SATTA A, FAEDDA R, CHIANDUSSI L, BARTOLI E: Fluid and electrolytes in liver disease. Postgrad. Med. J. (1983) 59/4:B1-B72.
   Web of Science ®Google Scholar
• BRENSING KA, TEXTOR J, PERZ J et al.: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a Phase II study. Gut (2000) 47:288-295.
   PubMed Web of Science ®Google Scholar
• SCHROEDER ET, ANDERSON GH JR, SMULYAN H: Effects of portocaval or peritoneovenous shunt on renin in the hepatorenal syndrome. Kidney Int. (1979) 15:54-61.
   PubMed Web of Science ®Google Scholar
• WONG F, PANTEA L, SNIDERMAN K: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and Type 1 hepatorenal syndrome. Hepatology (2004) 40:55-64.
   PubMed Web of Science ®Google Scholar
• DIBONA GF, KNOPP UC: Neural control of renal function. Physiol. Rev. (1997) 77:75-197.
   PubMed Web of Science ®Google Scholar
• ROMANO G, FAVRET G, DAMATO R, BARTOLI E: Proximal reabsorption with changing tubular fluid inflow in rat nephrons. Exp. Physiol. (1998) 83:35-48.
   PubMed Web of Science ®Google Scholar
• NELSON LD, OSBORN JL: Role of intrarenal ANG II in reflex neural stimulation of plasma renin activity and renal sodium reabsorption. Am. J. Physiol. (1993) 265:R392-R398.
   Google Scholar
• LEVY M, ALLOTEY JK: Temporal relationship between urinary salt retention and altered systemic hemodynamics in dogs with experimental cirrhosis. J. Lab. Clin. Med. (1978) 92:560-569.
   PubMed Web of Science ®Google Scholar
• MOORE K, WENDON J, FRAZER M, KARANI J, WILLIAMS R, BADR K: Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N. Engl. J. Med. (1992) 17:1774-1778.
   Google Scholar
• CAVARAPE A, BARTOLI E: Effects of BQ-123 on systemic and renal hemodynamic responses to endothelin-1 in the rat split hydronephrotic kidney. J. Hypertension (1998) 16:1449-1458.
   PubMed Web of Science ®Google Scholar
• WONG F, BLENDIS L: New challenge of hepatorenal syndrome: prevention and treatment. Hepatology (2001) 34:1242-1251.
   PubMed Web of Science ®Google Scholar
• SCHRIER RW, NIEDERBERGER M, WEIGERT A, GINES P: Peripheral arterial vasodilation: determinant of functional spectrum of cirrhosis. Semin. Liver. Dis. (1994) 14:14-22.
   PubMed Web of Science ®Google Scholar
• URIZ J, GINES P, CARDENAS A et al.: Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J. Hepatol. (2000) 33:43-48.
   PubMed Web of Science ®Google Scholar
• COLLE I, DURAND F, PESSIONE F et al.: Clinical course, predictive factors and prognosis in patients with cirrhosis and Type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J. Gastroenterol. Hepatol. (2002) 17:882-888.
   PubMed Web of Science ®Google Scholar
• GUEVARA M, GINES P, FERNANDEZ-ESPARRACH G et al.: Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology (1998) 27:35-41.
   PubMed Web of Science ®Google Scholar
• MCCORMICK PA, CHIN J, GREENSLADE L et al.: Cardiovascular effects of octreotide in patients with hepatic cirrhosis. Hepatology (1995) 21:1255-1260.
   PubMed Web of Science ®Google Scholar
• HUMPHREYS MH, AL-BANDER H, ENEAS JF, SCHAMBELAN M: Factors determining electrolyte excretion and renin secretion after closure of an arteriovenous fistula in the dog. J. Lab. Clin. Med. (1981) 98:89-98.
   PubMed Web of Science ®Google Scholar
• GELLAI M, EDWARDS BR, VALTIN H: Urinary concentrating ability during dehydration in the absence of vasopressin. Am. J. Physiol. (1979) 237:F100-F104.
   Google Scholar
• CASTELLO L, PIRISI M, SAINAGHI PP, BARTOLI E: Quantitative treatment of the hyponatremia of cirrhosis. Dig. Liver. Dis. (2005) 37:176-180.
   PubMedGoogle Scholar
• EARLEY LE, ORLOFF J: The mechanism of antidiuresis associated with the administration of hydrochlorothiazide to patients with vasopressin-resistant diabetes insipidus. J. Clin. Invest. (1962) 41:1988-1997.
   PubMed Web of Science ®Google Scholar
• CASTELLO L, PIRISI M, SAINAGHI PP, BARTOLI E: Hyponatremia in liver cirrhosis: pathophysiological principles of management. Dig. Liver. Dis. (2005) 37:73-81.
   PubMedGoogle Scholar
• SCHRIER RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephritic syndrome, cirrhosis, and pregnancy. N. Engl. J. Med. (1988) 319:1065-1072;1127-1134.
   PubMed Web of Science ®Google Scholar
• AGRE P, KOZONO D: Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett. (2003) 555:72-78.
   PubMed Web of Science ®Google Scholar
• VERKMAN AS: Lessons on renal physiology from transgenic mice lacking aquaporin water channels. J. Am. Soc. Nephrol. (1999) 10:1126-1135.
   PubMed Web of Science ®Google Scholar
• GUYADER D, PATAT A, ELLIS-GROSSE EJ, ORCZYK GP: Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology (2002) 36:1197-1205.
   PubMed Web of Science ®Google Scholar
• FERGUSON JW, THERAPONDOS G, NEWBY DE, HAYES PC: Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis. Clin. Sci. (2003) 105:1-8.
   PubMed Web of Science ®Google Scholar
• INOUE T, OHNISHI A, MATSUO A et al.: Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin. Pharmacol. Ther. (1998) 63:561-570.
   PubMed Web of Science ®Google Scholar
• THIBONNIER M, KILANI A, RAHMAN M et al.: Effects of the nonpeptide V1 vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension (1999) 34:1293-1300.
   PubMed Web of Science ®Google Scholar
• GINES P, GUEVARA M, ARROYO V, RODES J: Hepatorenal syndrome. Lancet (2003) 362:1819-1827.
   PubMed Web of Science ®Google Scholar
• RESTUCCIA T, ORTEGA R, GUEVARA MB et al.: Effects of treatment of hepatorenal syndrome before transplantation on postransplantation outcome. A case-control study. J. Hepatol. (2004) 40:140-146.
   PubMed Web of Science ®Google Scholar
• MOREAU R: The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. J. Hepatol. (2004) 40:159-161.
   PubMedGoogle Scholar
• THIBONNIER M: Vasopressin receptor antagonists in heart failure. Curr. Opin. Pharmacol. (2003) 3:683-687.
   PubMed Web of Science ®Google Scholar
• OHNISHI A, ORITA Y, OKAHARA R et al.: Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. (1993) 92:2653-2659.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-VARO G, ROS J, CEJUDO-MARTIN P et al.: Effect of the V1a/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J. Hepatol. (2003) 38:755-761.
   PubMed Web of Science ®Google Scholar
• JONASSEN TE, CHRISTENSEN S, KWON TH, LANGHOFF S, SALLING N, NIELSEN S: Renal water handling in rats with decompensated liver cirrhosis. Am. J. Physiol. Renal. Physiol. (2000) 279:F1101-F1109.
   Google Scholar
• GERBES AL, GULBERG V, GINES P et al.: VPA Study Group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology (2003) 124:933-939.
   PubMed Web of Science ®Google Scholar
• ANGELI P, VOLPIN R, GERUNDA G et al.: Reversal of Type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology (1999) 29:1690-1697.
   PubMed Web of Science ®Google Scholar
• DUVOUX C, ZANDITENAS D, HEZODE C et al.: Effects of noradrenalin and albumin in patients with Type I hepatorenal syndrome: a pilot study. Hepatology (2002) 36:374-380.
   PubMed Web of Science ®Google Scholar
• MANNING M, SAWYER WH: Discovery, development and some uses of vasopressin and oxytocine antagonists. J. Lab. Clin. Med. (1989) 114:617-632.
   PubMed Web of Science ®Google Scholar
• GADANO A, MOREAU R, PESSIONE F et al.: Aquaretic effects of niravoline, a κ-opioid agonist, in patients with cirrhosis. J. Hepatol. (2000) 32:38-42
   PubMedGoogle Scholar
• BOSCH-MARCE M, POO JL, JIMENEZ W et al.: Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J. Pharmacol. Exp. Ther. (1999) 289:194-201
   PubMed Web of Science ®Google Scholar
• HADRUP N, PETERSEN JS, PRAETORIUS J et al.: Opioid receptor-like 1 stimulation in the collecting duct induces aquaresis through vasopressin-independent aquaporin-2 downregulation. Am. J. Physiol. Renal. Physiol. (2004) 287:F160-F168.
   Web of Science ®Google Scholar
• PEREZ-AYUSO RM, ARROYO V, CAMPS J et al.: Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics. Nephron (1984) 36:30-37.
   PubMed Web of Science ®Google Scholar
• GHEORGHIADE M, NIAZI I, OUYANG J et al.: Tolvaptan investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation (2003) 107:2690-2696.
   PubMed Web of Science ®Google Scholar
• WONG F, BLEI AT, BLENDIS LM, THULUVATH PJ: A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology (2003) 37:182-191.
   PubMed Web of Science ®Google Scholar
• MARTIN PY, ABRAHAM WT, LIEMING X et al.: Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J. Am. Soc. Nephrol. (1999) 10:2165-2170.
   PubMed Web of Science ®Google Scholar
• BENGA G: Birth of water channel proteins – the aquaporins. Cell. Biol. Int. (2003) 27:701-709.
   PubMed Web of Science ®Google Scholar
• MACEY RI, FARMER RE: Inhibition of water and solute permeability in human red cells. Biochim. Biophys. Acta (1970) 211:104-106.
   PubMed Web of Science ®Google Scholar
• VALLON V, VERKMAN AS, SCHNERMANN J: Luminal hypotonicity in proximal tubules of aquaporin-1-knockout mice. Am. J. Physiol. Renal Physiol. (2000) 278:F1030-F1033.
   Google Scholar